ArticleThe pharmacogenomics journal2005
Sequencing drug response with HapMap.
Article in The pharmacogenomics journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 50 citations in OpenAlex.
- Association of SNP-SNP Interactions of Surfactant Protein Genes with Pediatric Acute Respiratory Failure.Journal of clinical medicine · 2020Article
- A unified mapping framework of multifaceted pharmacodynamic responses to hypertension interventions.Drug discovery today · 2019Review
- Mapping genes for drug chronotherapy.Drug discovery today · 2018Review
- DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.Oncotarget · 2016Review
- Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma.The pharmacogenomics journal · 2015Article
- Mapping asthma-associated variants in admixed populations.Frontiers in genetics · 2015Review
- Stochastic modeling of systems mapping in pharmacogenomics.Advanced drug delivery reviews · 2013Article
- A conceptual framework for pharmacodynamic genome-wide association studies in pharmacogenomics.Drug discovery today · 2011Review
- The genetics of congestive heart failure.Heart failure clinics · 2010Review
- Using a pharmacokinetic model to relate an individual's susceptibility to alcohol dependence to genotypes.Human heredity · 2010Article
- A statistical model for the identification of genes governing the incidence of cancer with age.Theoretical biology & medical modelling · 2008Article
- A general quantitative genetic model for haplotyping a complex trait in humans.Current genomics · 2007Article
- Pharmacogenomics and nutrigenomics: synergies and differences.European journal of clinical nutrition · 2007Review
- Theoretical basis for the identification of allelic variants that encode drug efficacy and toxicity.Genetics · 2005Article
- The zebrafish: scalable in vivo modeling for systems biology.Wiley interdisciplinary reviews. Systems biology and medicineReview
- Pharmacogenetics and the concept of individualized medicine.The pharmacogenomics journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The information about how DNA sequence varies across the human genome is crucial for unravelling the genetic basis of drug response. A haplotype map, or HapMap, intended to reveal such a variation pattern, has been recently developed by the International HapMap Consortium. Here, we present a conceptual model for directly characterizing specific DNA sequence variants that are responsible for drug response based on the haplotype structure provided by HapMap. Our model is developed in the maximum likelihood context, incorporated by clinically meaningful mathematical functions that model drug response and implemented with the EM algorithm. Our model is employed to a pharmacogenetic study of cardiovascular disease with 107 patients. We found that the haplotype constituted by allele Gly16 (G) at codon 16 and allele Glu27 (G) at codon 27 genotyped within the beta2AR candidate gene exhibits a different effect on heart rate curve from the rest haplotypes. Parents with the diplotype consisting of two copies of haplotype GG are more sensitive in heart rate to increasing dosages of dobutamine than those with other haplotypes. This model provides a powerful tool for elucidating the genetic variants of drug response and ultimately designing personalized medications based on each patient's genetic constitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.